6533b7dcfe1ef96bd1272bee

RESEARCH PRODUCT

In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii

Jorge GalvezVictoria DomínguezJesus-vicente De Julián-ortizRemedios GunaCarlos Fuertes MuñozRafael BorrásÁNgeles García-garcía

subject

Microbiology (medical)MoxifloxacinMicrobial Sensitivity TestsBiologyMicrobiologychemistry.chemical_compoundMoxifloxacinClarithromycinClarithromycinAcetamidesDrug Resistance Bacterialpolycyclic compoundsmedicineHumansheterocyclic compoundsPharmacology (medical)OxazolidinonesEthambutolAntibacterial agentPharmacologyMycobacterium kansasiiAza CompoundsIsoniazidLinezolidbiochemical phenomena metabolism and nutritionbacterial infections and mycosesbiology.organism_classificationAnti-Bacterial AgentsInfectious DiseaseschemistryMycobacterium kansasiiLinezolidQuinolinesbacteriaRifampicinFluoroquinolonesmedicine.drug

description

To compare the activity of linezolid with a range of drugs used in the treatment of Mycobacterium kansasii infections.The percentages of resistant isolates against isoniazid, rifampicin and ethambutol were 2.9%, 1.9% and 2.9%, respectively. All isolates were susceptible to clarithromycin and moxifloxacin both with MIC(90) values of 0.125 mg/L. Linezolid was active against all isolates with MIC(50) and MIC(90) values of 0.5 and 1 mg/L, respectively, both below the susceptibility breakpoint established for mycobacteria.Linezolid, clarithromycin or moxifloxacin, could be used as alternative drugs for treatment of infections due to rifampicin-resistant isolates as well as short-course or intermittent therapy of M. kansasii lung disease.

yearjournalcountryeditionlanguage
2005-04-13Journal of Antimicrobial Chemotherapy
https://doi.org/10.1093/jac/dki111